Literature DB >> 3357944

Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy.

C A Staples1, N L Müller, R R Miller, K G Evans, B Nelems.   

Abstract

Computed tomography (CT) and mediastinoscopy were compared in 151 patients with bronchogenic carcinoma. In all patients in whom findings at mediastinoscopy were negative, all accessible nodes were either removed or sampled at thoracotomy. Several size criteria for identifying nodes as enlarged on CT scans were compared. The long axis greater than or equal to 15 mm and short axis greater than 10 mm had very low sensitivity (61%), and the long axis greater than 5 mm had a low specificity (23%). CT (long axis greater than 10 mm) allowed sensitivity equal to that of mediastinoscopy (79%) in the detection of mediastinal metastases, but the specificity with CT was lower (65% vs. 100%). In seven of 44 patients with nodes greater than 10 mm on CT scans and with positive findings at mediastinoscopy, tumor was present not in the enlarged nodes but rather in normal-sized nodes in a different nodal station. The sensitivity of CT for actual nodal stations involved with tumor was only 66%. Eighty-three percent of patients with false-negative findings at mediastinoscopy but only 33% of patients with false-negative findings at CT had surgically resectable stage IIIa disease.

Entities:  

Mesh:

Year:  1988        PMID: 3357944     DOI: 10.1148/radiology.167.2.3357944

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  20 in total

Review 1.  Ultrasound techniques in the evaluation of the mediastinum, part I: endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS) and transcutaneous mediastinal ultrasound (TMUS), introduction into ultrasound techniques.

Authors:  Christoph Frank Dietrich; Jouke Tabe Annema; Paul Clementsen; Xin Wu Cui; Mathias Maximilian Borst; Christian Jenssen
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

2.  Mediastinoscopy as a predictor of resectability in patients with bronchogenic carcinoma.

Authors:  D S Ríordáin; D J Buckley; T Aherne
Journal:  Ir J Med Sci       Date:  1991-09       Impact factor: 1.568

Review 3.  Combined PET/MRI: a new dimension in whole-body oncology imaging?

Authors:  Gerald Antoch; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

4.  The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography.

Authors:  M Sasaki; Y Ichiya; Y Kuwabara; Y Akashi; T Yoshida; T Fukumura; S Murayama; T Ishida; K Sugio; K Masuda
Journal:  Eur J Nucl Med       Date:  1996-07

5.  Utility and accuracy of endobronchial ultrasound as a diagnostic and staging tool for the evaluation of mediastinal adenopathy.

Authors:  William D Bolton; Rebecca Johnson; Elizabeth Banks; Shelly Hutcheson; Weston Wall; James Stephenson
Journal:  Surg Endosc       Date:  2012-12-13       Impact factor: 4.584

6.  Cost-effectiveness associated with the diagnosis and staging of non-small-cell lung cancer.

Authors:  H Osada; K Kojima; H Tsukada; Y Nakajima; K Imamura; J Matsumoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-01

7.  Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy.

Authors:  A Abramyuk; S Appold; K Zöphel; M Baumann; N Abolmaali
Journal:  Strahlenther Onkol       Date:  2013-01-19       Impact factor: 3.621

8.  Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer.

Authors:  Candice C Black; Mary Jo Turk; Konstantin Dragnev; James R Rigas
Journal:  Lung       Date:  2013-03-15       Impact factor: 2.584

Review 9.  Staging of bronchogenic carcinoma.

Authors:  S J Herman
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

Review 10.  Nodal staging.

Authors:  Skandadas Ganeshalingam; Dow-Mu Koh
Journal:  Cancer Imaging       Date:  2009-12-24       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.